In Parallel to the clinical development, Algenis is exploring new uses for these molecules in the following areas:

  1. Loss of Sensitivity caused by Peripheral Neuropathy Induced by Chemotherapy Treatments (CIPN): CIPN induce several symptoms. Some of them as paresthesia, dysesthesia, numbness and tingling that can progress to sensory and motor impairments, and finally pain. At present, there are no FDA approved therapies for CIPN and the widely prescribed non approved drugs used do not fulfil the clinical criterion for its use in this indication. Algenis has initiated an investigation to develop a new therapy to recover the tactile sensitivity, based on these molecules.
  2. Acute Nociceptive Pain represents an important challenge to the world health. In the world, an estimated 1 out of 5 adults suffers some sort of pain and 1 out of 10 adults is diagnosed of Chronic Pain every year. Algenis’s NAVX-010 (Injectable GTX 2&3) is a candidate therapy for acute nociceptive pain treatment with encouraging results, showing favorable effects on pain intensity, lumbar functionality, and reduction in the use of pain rescue drugs. NAVX-010 has successfully completed its Preclinical and Phase I Clinical Trials in the US.
  3. Anti-wrinkles Cosmetic. Algenis developed a formulation based on a micro algae extract to reduce wrinkles of the front head. The product was tested in a blinded pilot clinical study, on volunteers (n=12, 43 - 67 years old, 4 weeks treatment) in Germany, where it demonstrated good safety and efficacy results. 58% of the volunteers showed a reduction of ≥20% in wrinkles and 30% got a relaxant effect on the skin and tensor effect. After 4 weeks of application, there was an appreciable improvement in skin texture in 75% of the volunteers. In addition, validated cutaneous penetration assays performed by MedPharm (USA) demonstrated that GTX 2&3, present in Algenis formulation, have a dose dependent penetration in the dermis and the epidermis.